These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 9515185)

  • 1. Clinical pharmacokinetics of fibric acid derivatives (fibrates).
    Miller DB; Spence JD
    Clin Pharmacokinet; 1998 Feb; 34(2):155-62. PubMed ID: 9515185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.
    Williams D; Feely J
    Clin Pharmacokinet; 2002; 41(5):343-70. PubMed ID: 12036392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug interactions with fibric acids.
    Lozada A; Dujovne CA
    Pharmacol Ther; 1994 Aug; 63(2):163-76. PubMed ID: 7809177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Currently available hypolipidaemic drugs and future therapeutic developments.
    Farmer JA; Gotto AM
    Baillieres Clin Endocrinol Metab; 1995 Oct; 9(4):825-47. PubMed ID: 8593127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical pharmacokinetics of atorvastatin.
    Lennernäs H
    Clin Pharmacokinet; 2003; 42(13):1141-60. PubMed ID: 14531725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteins.
    Zimetbaum P; Frishman WH; Kahn S
    J Clin Pharmacol; 1991 Jan; 31(1):25-37. PubMed ID: 2045526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions.
    Kosoglou T; Statkevich P; Johnson-Levonas AO; Paolini JF; Bergman AJ; Alton KB
    Clin Pharmacokinet; 2005; 44(5):467-94. PubMed ID: 15871634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of fibric acid derivatives on blood lipid and lipoprotein levels.
    Hunninghake DB; Peters JR
    Am J Med; 1987 Nov; 83(5B):44-9. PubMed ID: 3318453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacokinetics of fluvastatin.
    Scripture CD; Pieper JA
    Clin Pharmacokinet; 2001; 40(4):263-81. PubMed ID: 11368292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Drug interactions with antilipemics].
    Becquemont L
    Therapie; 2003; 58(1):85-90. PubMed ID: 12822205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential use of fenofibrate and other fibric acid derivatives in the clinic.
    Brown WV
    Am J Med; 1987 Nov; 83(5B):85-9. PubMed ID: 3688012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fenofibrate in the treatment of dyslipidemia: a review of the data as they relate to the new suprabioavailable tablet formulation.
    Najib J
    Clin Ther; 2002 Dec; 24(12):2022-50. PubMed ID: 12581543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of gemfibrozil and fenofibrate on the pharmacokinetics of atorvastatin.
    Whitfield LR; Porcari AR; Alvey C; Abel R; Bullen W; Hartman D
    J Clin Pharmacol; 2011 Mar; 51(3):378-88. PubMed ID: 20413454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia.
    Perreault S; Hamilton VH; Lavoie F; Grover S
    Cardiovasc Drugs Ther; 1997 Jan; 10(6):787-94. PubMed ID: 9110123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Micronized fenofibrate: a new fibric acid hypolipidemic agent.
    Guay DR
    Ann Pharmacother; 1999 Oct; 33(10):1083-103. PubMed ID: 10534222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia.
    Keating GM; Ormrod D
    Drugs; 2002; 62(13):1909-44. PubMed ID: 12215067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors.
    Garnett WR
    Am J Health Syst Pharm; 1995 Aug; 52(15):1639-45. PubMed ID: 7583826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin + fibrate (bezafibrate, fenofibrate, or gemfibrozil).
    Farnier M; Salko T; Isaacsohn JL; Troendle AJ; Dejager S; Gonasun L
    Am J Cardiol; 2003 Oct; 92(7):794-7. PubMed ID: 14516878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.